Ignite Creation Date:
2025-12-24 @ 11:49 PM
Ignite Modification Date:
2026-05-27 @ 4:27 AM
Study NCT ID:
NCT07120451
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-08-13
First Post:
2025-08-06
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Combination Therapy of Senaparib and Bevacizumab for First-line Maintenance Therapy in Newly Diagnosed Advanced Homologous Recombination Proficient Ovarian Cancer Based on Exosome Protein Marker
Sponsor:
Fudan University
Organization:
Organization Data
Organization:
Class:
OTHER
Study ID:
OC-SENABEV-HRP
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
OTHER
Responsible Party:
Responsible Party Title:
Responsible Party Type:
PRINCIPAL_INVESTIGATOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None